Sequence variation in the monoclonal-antibody-U36-defined CD44v6 epitope

Nicole L.W. Van Hal, Guus A.M.S. Van Dongen, Corlinda B.M. Ten Brink, Jim N. Herron, Gordon B. Snow, Ruud H. Brakenhoff

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Monoclonal antibody (mAb) U36 was developed for the treatment of minimal residual disease of head and neck squamous cell carcinoma (HNSCC). The mAb- U36-defined antigen was characterized by cDNA cloning, and was shown to be identical to the keratinocyte-specific CD44 splice variant epican. The epitope recognized by mAb U36 was shown to be located in the v6 domain. Two amino acids within the epitope appeared to differ from the sequences that have been described in literature. The sequence of the epitope appeared to contain glutamic acid at position 367 and lysine at position 374, while valine and arginine respectively have been described before. Interestingly, another anti-CD44v6 antibody with possible clinical application, VFF18, recognizes an epitope in the same area. With respect to the applicability of these antibodies for tumor targeting, this variation might have an influence on antibody-antigen interaction and mAb accumulation in the tumor. Furthermore, this observation raised the question whether the different epitopes are related to the malignant behavior of tumor cells. In this paper we determine the relative affinity of mAb U36 for the variant epitope sequences by tumor cell binding assays using synthetic peptides for competition. The presence of glutamic acid instead of valine at position 367 caused strong competition. Further evaluation showed that the published valine variant does not exist in vivo, and is the result of a sequencing artefact. The effect of substitution of lysine for arginine at position 374 had no effect on the binding of mAb U36 to the cells. This amino acid variation was shown to be due to allelic polymorphism. There was no trend towards allelic imbalance in tumor cells as compared to normal cells.

Original languageEnglish
Pages (from-to)88-92
Number of pages5
JournalCancer Immunology Immunotherapy
Volume45
Issue number2
DOIs
Publication statusPublished - 2 Dec 1997

Cite this

Van Hal, Nicole L.W. ; Van Dongen, Guus A.M.S. ; Ten Brink, Corlinda B.M. ; Herron, Jim N. ; Snow, Gordon B. ; Brakenhoff, Ruud H. / Sequence variation in the monoclonal-antibody-U36-defined CD44v6 epitope. In: Cancer Immunology Immunotherapy. 1997 ; Vol. 45, No. 2. pp. 88-92.
@article{1c916ef677c74e19a6ffc6aeb6e07f35,
title = "Sequence variation in the monoclonal-antibody-U36-defined CD44v6 epitope",
abstract = "Monoclonal antibody (mAb) U36 was developed for the treatment of minimal residual disease of head and neck squamous cell carcinoma (HNSCC). The mAb- U36-defined antigen was characterized by cDNA cloning, and was shown to be identical to the keratinocyte-specific CD44 splice variant epican. The epitope recognized by mAb U36 was shown to be located in the v6 domain. Two amino acids within the epitope appeared to differ from the sequences that have been described in literature. The sequence of the epitope appeared to contain glutamic acid at position 367 and lysine at position 374, while valine and arginine respectively have been described before. Interestingly, another anti-CD44v6 antibody with possible clinical application, VFF18, recognizes an epitope in the same area. With respect to the applicability of these antibodies for tumor targeting, this variation might have an influence on antibody-antigen interaction and mAb accumulation in the tumor. Furthermore, this observation raised the question whether the different epitopes are related to the malignant behavior of tumor cells. In this paper we determine the relative affinity of mAb U36 for the variant epitope sequences by tumor cell binding assays using synthetic peptides for competition. The presence of glutamic acid instead of valine at position 367 caused strong competition. Further evaluation showed that the published valine variant does not exist in vivo, and is the result of a sequencing artefact. The effect of substitution of lysine for arginine at position 374 had no effect on the binding of mAb U36 to the cells. This amino acid variation was shown to be due to allelic polymorphism. There was no trend towards allelic imbalance in tumor cells as compared to normal cells.",
keywords = "Antibody-based therapy, CD44v6, Epitope variation, Squamous cell carcinoma, Tumor targeting",
author = "{Van Hal}, {Nicole L.W.} and {Van Dongen}, {Guus A.M.S.} and {Ten Brink}, {Corlinda B.M.} and Herron, {Jim N.} and Snow, {Gordon B.} and Brakenhoff, {Ruud H.}",
year = "1997",
month = "12",
day = "2",
doi = "10.1007/s002620050406",
language = "English",
volume = "45",
pages = "88--92",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "2",

}

Sequence variation in the monoclonal-antibody-U36-defined CD44v6 epitope. / Van Hal, Nicole L.W.; Van Dongen, Guus A.M.S.; Ten Brink, Corlinda B.M.; Herron, Jim N.; Snow, Gordon B.; Brakenhoff, Ruud H.

In: Cancer Immunology Immunotherapy, Vol. 45, No. 2, 02.12.1997, p. 88-92.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Sequence variation in the monoclonal-antibody-U36-defined CD44v6 epitope

AU - Van Hal, Nicole L.W.

AU - Van Dongen, Guus A.M.S.

AU - Ten Brink, Corlinda B.M.

AU - Herron, Jim N.

AU - Snow, Gordon B.

AU - Brakenhoff, Ruud H.

PY - 1997/12/2

Y1 - 1997/12/2

N2 - Monoclonal antibody (mAb) U36 was developed for the treatment of minimal residual disease of head and neck squamous cell carcinoma (HNSCC). The mAb- U36-defined antigen was characterized by cDNA cloning, and was shown to be identical to the keratinocyte-specific CD44 splice variant epican. The epitope recognized by mAb U36 was shown to be located in the v6 domain. Two amino acids within the epitope appeared to differ from the sequences that have been described in literature. The sequence of the epitope appeared to contain glutamic acid at position 367 and lysine at position 374, while valine and arginine respectively have been described before. Interestingly, another anti-CD44v6 antibody with possible clinical application, VFF18, recognizes an epitope in the same area. With respect to the applicability of these antibodies for tumor targeting, this variation might have an influence on antibody-antigen interaction and mAb accumulation in the tumor. Furthermore, this observation raised the question whether the different epitopes are related to the malignant behavior of tumor cells. In this paper we determine the relative affinity of mAb U36 for the variant epitope sequences by tumor cell binding assays using synthetic peptides for competition. The presence of glutamic acid instead of valine at position 367 caused strong competition. Further evaluation showed that the published valine variant does not exist in vivo, and is the result of a sequencing artefact. The effect of substitution of lysine for arginine at position 374 had no effect on the binding of mAb U36 to the cells. This amino acid variation was shown to be due to allelic polymorphism. There was no trend towards allelic imbalance in tumor cells as compared to normal cells.

AB - Monoclonal antibody (mAb) U36 was developed for the treatment of minimal residual disease of head and neck squamous cell carcinoma (HNSCC). The mAb- U36-defined antigen was characterized by cDNA cloning, and was shown to be identical to the keratinocyte-specific CD44 splice variant epican. The epitope recognized by mAb U36 was shown to be located in the v6 domain. Two amino acids within the epitope appeared to differ from the sequences that have been described in literature. The sequence of the epitope appeared to contain glutamic acid at position 367 and lysine at position 374, while valine and arginine respectively have been described before. Interestingly, another anti-CD44v6 antibody with possible clinical application, VFF18, recognizes an epitope in the same area. With respect to the applicability of these antibodies for tumor targeting, this variation might have an influence on antibody-antigen interaction and mAb accumulation in the tumor. Furthermore, this observation raised the question whether the different epitopes are related to the malignant behavior of tumor cells. In this paper we determine the relative affinity of mAb U36 for the variant epitope sequences by tumor cell binding assays using synthetic peptides for competition. The presence of glutamic acid instead of valine at position 367 caused strong competition. Further evaluation showed that the published valine variant does not exist in vivo, and is the result of a sequencing artefact. The effect of substitution of lysine for arginine at position 374 had no effect on the binding of mAb U36 to the cells. This amino acid variation was shown to be due to allelic polymorphism. There was no trend towards allelic imbalance in tumor cells as compared to normal cells.

KW - Antibody-based therapy

KW - CD44v6

KW - Epitope variation

KW - Squamous cell carcinoma

KW - Tumor targeting

UR - http://www.scopus.com/inward/record.url?scp=0030695105&partnerID=8YFLogxK

U2 - 10.1007/s002620050406

DO - 10.1007/s002620050406

M3 - Article

VL - 45

SP - 88

EP - 92

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 2

ER -